CD8A and Parkinson disease: We first analyzed the possible correlation between the frequency of CD8 TEMRA and various available quantitative clinical parameters, such as age, disease duration, H&Y staging scale, UPDRS-III (Unified Parkinson’s Disease Rating Scale III), LEDD (Levodopa equivalent daily dose) and MOCA (Montreal Cognitive Assessment).